Journal article

NET silencing by let-7i in postural tachycardia syndrome

Abdul Waheed Khan, Mark Ziemann, Susan J Corcoran, KN Harikrishnan, Jun Okabe, Haloom Rafehi, Scott S Maxwell, Murray D Esler, Assam El-Osta

JCI INSIGHT | AMER SOC CLINICAL INVESTIGATION INC | Published : 2017

Abstract

While strongly implicated in postural tachycardia syndrome (POTS), considerable controversy exists regarding norepinephrine transporter (NET) loss of function. POTS is characterized by the clinical symptoms of orthostatic intolerance, lightheadedness, tachycardia, and syncope or near syncope with upright posture. Abnormal sympathetic nervous system activity is typical, of a type which suggests dysfunction of the NET, with evidence that the gene responsible is under tight epigenetic control. Using RNA of isolated chromatin combined with massive parallel sequencing (RICh-seq) we show that let-7i miRNA suppresses NET by methyl-CpG-binding protein 2 (MeCP2). Vorinostat restores epigenetic contro..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Health and Medical Research Council (NHMRC)


Awarded by NHMRC-NFSC


Funding Acknowledgements

We would like to acknowledge Gautam Vaddadi and Elisabeth Lambert (Baker IDI Heart and Diabetes Institute) who performed the head-up tilt (HUT) studies. This study was supported by a National Health and Medical Research Council (NHMRC) program grant ME, research fellowship AE (1070386 and APP0526681), and NHMRC-NFSC joint program AE (APP1113188). This work was supported in part by the Victorian Government's Operational Infrastructure Support Program.